Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 28/10/2020
SIETES contiene 93136 citas

 
 
 1 a 20 de 40 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Hwang TJ, Ross JS, Vokinger KN, Kesselheim AS. Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study. BMJ 2020;371:7 de octubre. [Ref.ID 103742]
2.Enlace a cita original Cita con resumen
Avorn J, Kesselheim AS. Up Is down — Pharmaceutical industry caution vs. Federal acceleration of Covid-19 vaccine approval. N Engl J Med 2020;383:29 de octubre. [Ref.ID 103719]
3.Enlace a cita originalTiene citas relacionadas Cita con resumen
Dal-Ré R, Kesselheim AS, Bourgeois FT. Increasing access to FDA inspection reports on irregularities and misconduct in clinical trials. JAMA 2020:23 de abril. [Ref.ID 103599]
5.Enlace a cita original Cita con resumen
Desai RJ, Sarpatwari A, Dejene S, Khan NF, Lii J, Rogers JR, Dutcher SK, Raofi S, Bohn J, Connolly JG, Fischer MA, Kesselheim AS, Gagne JJ. Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims. PLOS Medicine 2019:13 de marzo. [Ref.ID 103076]
6.Enlace a cita original Cita con resumen
Beall RF, Hwang TJ, Kesselheim AS. Major events in the life course of new drugs, 2000–2016. N Engl J Med 2019;380:14 de marzo. [Ref.ID 103056]
7. Cita con resumen
Darrow JJ, Avorn J, Kesselheim AS. The FDA breakthrough-drug designation - Four years of experience. N Engl J Med 2018;378:16 de abril. [Ref.ID 102515]
10. Cita con resumen
Fralick M, Avorn J, Kesselheim AS. The price of crossing the border for medications. N Engl J Med 2017;377:311-3. [Ref.ID 101925]
11. Cita con resumen
Kesselheim AS, Donneyong M, Dal Pan GJ, Zhou EH, Avorn J, Schneeweiss S, Seeger JD. Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications. Pharmacoepidemiol Drug Saf 2017;26:712-21. [Ref.ID 101627]
12. Cita con resumen
Hwang TJ, Carpenter D, Lauffenburger JC, Wang B, Franklin JM, Kesselheim AS. Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Intern Med 2016;176:1826-33. [Ref.ID 100788]
13. Cita con resumen
Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA 2016;316:858-71. [Ref.ID 100589]
14. Cita con resumen
Kesselheim AS, Wang B, Franklin JM, Darrow JJ. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study. BMJ 2015;351:h4633. [Ref.ID 99588]
15. Cita con resumen
Kesselheim AS, Laggs LR, Sarpatwari A. Experience with the priority review voucher program for drug development. JAMA 2015;314:27 de octubre. [Ref.ID 99526]
16. Cita con resumen
Avorn J, Sarpatwari A, Kesselheim AS. Forbidden and permitted statements about medications - Loosening the rules. N Engl J Med 2015;373:967-73. [Ref.ID 99432]
17.Tiene citas relacionadas Cita con resumen
Sharfstein JM, Kesselheim AS. The safety of prescription drugs. JAMA 2015;314:233-4. [Ref.ID 99359]
18. Cita con resumen
Sarpatwari A, Avorn J, Kesselheim AS. Progress and hurdles for follow-on biologics. N Engl J Med 2015;372:2380-2. [Ref.ID 99297]
19. Cita con resumen
Kesselheim AS, Campbell EG, Schneeweiss S, Rausch P, Lappin BM, Zhou EH, Seeger JD, Brownstein JS, Woloshin S, Schwartz LM, Toomey T, Dal Pan GJ, Avorn J. Methodological approaches to evaluate the impact of FDA drug safety communications. Drug Saf 2015;38:565-75. [Ref.ID 99239]
20. Cita con resumen
Kesselheim AS, Bykov K, Avorn J, Tong A, Doherty M, Choudhry NK. Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case - control studies. Ann Intern Med 2014;161:96-103. [Ref.ID 97814]
Seleccionar todas
 
 1 a 20 de 40 siguiente >>